[Is resistance of human immunodeficiency viruses (HIV) to nucleoside analogs an indication for their combined use?]

J M Pépin; F Simon; F Brun-Vezinet

[Is resistance of human immunodeficiency viruses (HIV) to nucleoside analogs an indication for their combined use?]

Pathol Biol (Paris). 1993 Oct;41(8 Pt 2):788-93.

[Article in French]

Authors

J M Pépin¹, F Simon, F Brun-Vezinet

Affiliation

¹ Laboratoire de Virologie, Hôpital Bichat-Claude Bernard, Paris, France.

PMID: 8309722

Abstract

HIV resistance to nucleoside analogues such as zidovudine (AZT) is to date a source of concern, even if its clinical significance is yet to be determined. Phenotypic and genotypic data concerning HIV resistance will be presented, then the potential benefits of nucleoside combinations will be discussed.

Publication types

English Abstract
Review

MeSH terms

Acyclovir / pharmacology
Didanosine / pharmacology*
Drug Synergism
Drug Therapy, Combination
Female
Foscarnet / pharmacology
HIV-1 / drug effects*
Humans
In Vitro Techniques
Male
Ribavirin / pharmacology*
Zalcitabine / pharmacology*
Zidovudine / pharmacology*

Substances

Foscarnet
Ribavirin
Zidovudine
Zalcitabine
Didanosine
Acyclovir